During this fireside chat we welcome Mesoblast Limited (Nasdaq: MESO). Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions.
This fireside chat was recorded during the Lytham Partners 2025 Investor Healthcare Summit.